Jan 9 Celgene Corp raised its 2017
revenue and profit forecasts, as the company benefits from new
patient market share gains for its flagship multiple myeloma
The Summit, New Jersey-based company said on Monday it
expected earnings per share of $7.10-$7.25 and revenue of $13.0
billion-$13.4 billion for 2017.
Celgene had previously forecast full-year earnings of
$6.75-$7.00 per share and net product sales of $12.7
Revlimid's net sales are expected in the range of $8.0
billion to $8.3 billion for 2017.
(Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by